Product apis-mark

Home > products > apis> mark

Catalog	name	Description	price
R-C-644	BIX02189 CAS:1094614-85-3	BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM,also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays,and does not inhibit closely related kinases MEK1,MEK2,ERK2,and JNK2.	price>
R-C-662	TAK632 cas: 1228591-30-7	TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50,2.4 nM;BRAF(wt),8.3 nM; CRAF,1.4 nM; pMEK (A375) IC50,12 nM;pMEK (HMVII), 49 nM;V/B ratio.	price>
R-C-739	SCH-772984 CAS No. 942183-80-4	SCH772984 is a novel,specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay,respectively,And show robust efficacy in RAS-or BRAF-mutant cancer cells.	price>
R-C-1011	B-RAF cas:1093100-40-3	BRAF is a human gene that encodes a protein called B-Raf.The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B,while the protein is more formally known as serine/threonine-protein kinase B-Raf.	price>
R-C-1012	Losmapimod(GW-856553) cas:585543-15-3	Losmapimod,also know as GW856553 or GW856553X,is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases.	price>
R-C-1034	Ulixertinib (BVD-523) CAS No. 869886-67-9	Ulixertinib is an orally available inhibitor of extracellular signal-regulated kinase(ERK)1 and 2,with potential antineoplastic activity.Upon oral administration,ulixertinib inhibits both ERK 1 and 2,thereby preventing the activation of ERK-mediated signal transduction pathways.This results in the inhibition of ERK-dependent tumor cell proliferation and survival.The mitogen-activated protein kinase(MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	price>
R-C-1099	JNK Inhibitor IX CAS：312917-14-9	JNK Inhibitor IX is a thienylnaphthamide compound that is a selective and potent inhibitor of the ATP binding site of JNK2 and JNK3.JNK1,p38α and other kinases are effected slightly or not at all when JNK2 and JNK3 are inhibited by the JNK inhibitor IX.In comparison to SP600125(sc-200635),the inhibitor of JNK,JNK inhibitor IX is more selective between JNK1 and JNK3.The JNK pathway plays important roles in various cellular processes and is activated when cells are exposed to proinflammatory cytokines, environmental stress and different anticancer drugs.Research shows that JNK1,JNK2,and JNK3 are associated in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.	price>
R-C-1131	SB239063 CAS:193551-21-2	SB 239063 is a selective p38 MAPK inhibitor(IC50=44 nM for recombinant purified p38α).1 It displays greater than 220-fold selectivity for p38 MAPK over ERK, JNK1,and other kinases.1 SB 239063 has been shown to reduce inflammatory cytokine production in lipopolysaccharide-stimulated human peripheral blood monocytes(IC50s=0.12 and 0.35 µM,respectively for IL-1 and TNF-α)and is neuroprotective following oral administration in a rat model of cerebral focal ischemia.	price>
R-C-1144	URMC-099 CAS：1229582-33-5	URMC-099 is an orally bioavailable,brain penetrant mixed lineage kinase (MLK)inhibitor with IC50 of 19 nM,42 nM,14 nM,and 150 nM,for MLK1,MLK2,MLK3,and DLK,respectively,and also inhibits LRRK2 activity with IC50 of 11 nM.URMC-099 also inhibits ABL1 with IC50 of 6.8 nM.URMC-099 induces autophagy.	price>
R-C-1175	SB590885 CAS：405554-55-4	SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM,and has 11-fold greater selectivity for B-Raf over c-Raf,without inhibition to other human kinases.	price>

...